Abstract
Transmission of COVID-19 is facilitated by uptake of droplets containing coronavirus from the breath, sneeze or cough of infected persons. This represents the commonest mode of coronavirus infection and spread to mucous membranes of the respiratory system. The virus rapidly replicates in alveolar cells, triggering a strong immune response, resulting in cytokine storm syndromes and pulmonary tissue damage. These pathologic processes contribute to a compromised pulmonary function. Thus, evaluation of pulmonary function would give insights into modulatory effect of agents that may be beneficial in ameliorating this pathology. The study evaluated effects of Cov-Pla1 and Cov-Pla3 (polyherbal products of the research team, positioned for treatment of Covid-19) on pulmonary function in bleomycin-induced lung injury in rabbits. Rabbits of both sexes were divided into six groups and treated with the extracts alone or the extract following pre-treatment with bleomycin. Targeted respiratory function parameters were monitored at baseline and on day three. Vital capacity, tidal volume, inspiratory reserve volume and inspiratory capacity in the groups treated with Cov-Pla1 and Cov-Pla3 at 125 and 500 mg/kg respectively were compared with the bleomycin only group. In bleomycin pre-treated groups, the two preparations at 125 mg/kg showed increased vital capacity compared to the bleomyicn only group. This pattern was repeated with the other parameters that were evaluated. These results imply that Cov-Pla1 and Cov-Pla3 at the 125 mg/kg dose have ameliorative effects on bleomycin induced lung injury and could be beneficial in situations such as COVID-19 where there are active insults to the respiratory system. Keywords: COVID-19, Cov-Pla, Herbal Preparation, Respiratory function
Highlights
An infection caused by a viral organism that is referred to as the novel corona virus, known as the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) was discovered in China in late 2019.Afr
This infection has continued to ravage the world since the time, in pandemic proportions, and is known as COVID-19
The purpose of the study was to evaluate the effect of the poyherbal products (Cov-Pla1 and Cov-Pla3) on pulmonary function in the rabbit model of bleomycininduced lung injury
Summary
An infection caused by a viral organism that is referred to as the novel corona virus, known as the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) was discovered in China in late 2019.Afr. An infection caused by a viral organism that is referred to as the novel corona virus, known as the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) was discovered in China in late 2019. This infection has continued to ravage the world since the time, in pandemic proportions, and is known as COVID-19. Many symptoms of the infection have been reported in patients. These range from common symptoms such as fever, cough, myalgia or fatigue and pneumonia, often complicated with dyspnea. COVID-19 has defied all forms of treatment and there are currently no therapeutically effective drugs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
